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Dear Editor,  
 
Cervicovaginal fluid (CVF) fetal fibronectin (FFN) is a reliable test in asymptomatic high-risk 
women to help predict preterm birth (PTB). Urinary tract infections (UTI) are a treatable 
risk-factor for PTB risk. FFN is affected by recent intercourse1 or bleeding2, but it is unknown 
whether FFN results are affected by UTI. We hypothesized that levels of FFN in the CVF 
increases at the time of a UTI but subsequently recovers following treatment. We 
performed an exploratory longitudinal prospective study to test this.  
 
We studied consecutive women attending an inner-city Prematurity Surveillance Clinic and 
audited routine clinical tests. Women were high-risk due to previous history of PTB, late 
miscarriage, cervical surgery or uterine abnormalities. At each visit women provided a mid-
stream urine (MSU) which was dipped, and sent for prompt culture in boric acid containers 
if nitrite positive, leukocyte >1+, or clinician discretion.  Women were analysed if an MSU 
was sent. FFN was measured at each appropriate visit (18+0 to 34+6 weeks’ gestation3).  
 
Women with UTI (cases) were gestational age-matched with up to three controls (±2wks). 
To isolate the effect of UTI on FFN rather than impending PTB, we excluded women with 
with PTB <34 weeks (a major confounder to FFN). FFN values at the time of positive dipstick, 
and those 5 weeks before and after, were compared using random-effects GLS (Generalised 
Least Squares) regression using STATA 15.0.  
 
Of 394 high-risk women, 112 MSUs were cultured. 70 (62.5%) had no growth, 33 (29.5%) 
grew contaminants and 9 (8%) grew a causative organism. Of the nine cases, two were 
excluded due to lack of FFN and one excluded due to delivery <34 weeks’ gestation. The FFN 
of the woman who delivered <34wks rose to 200ng/mL at time of UTI, but recovered to 
16ng/mL two weeks later. Six cases were matched to sixteen controls and there were no 
recurrent UTIs.  
 
FFN appeared to increase over time in the controls, although remaining negative 
(<50ng/mL). Cases appeared to have higher FFNs at baseline and stepped up at time of 
infection. UTIs could therefore cause false positive (>50ng/mL) FFNs in women who do not 
deliver preterm. This, however, was not statistically significant as shown by the wide 
confidence intervals (Figure 1).  
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We gathered longitudinal data on 394 high-risk women, but only 2.3% had proven UTIs; 
suggesting that UTI is not a common concern in this group. This is relevant in the community 
where GPs may empirically treat a positive dip. There appeared to be an increase in FFN at 
time of infection, but to demonstrate an effect (3.2x FFN increase) with 80% power, 1400 
high-risk women would need to be screened. Given the very low prevalence of UTI in this 
high-risk group, the size of a trial that would be needed to prove an effect would be 
challenging.  
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